Harmony Biosciences Holdings

HRMY · NASDAQ

$38.70+$1.16 (+3.09%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $37.54

Latest news

Press releaseOct 12, 7:00 AM ETGlobe Newswire
Harmony Biosciences Announces Planned CEO Transition to Support Next Phase of Growth
NewsAug 5, 6:56 AM ETVandana Singh
Harmony Biosciences Says New Data Supports Neurology Pipeline
NewsAug 4, 7:32 AM ET
Harmony Biosciences Q2 EPS $1.28 Beats $0.94 Estimate, Sales $261.300M Beat $248.406M Estimate
Press releaseAug 4, 7:30 AM ETGlobe Newswire
Harmony Biosciences Announces Record Q2 2026 Revenue and Shares Initial Clinical Data for Its Orexin-2 Agonist BP-205 Reinforcing Potential Best-in-Class Profile
Press releaseJul 16, 8:30 AM ETBusiness Wire
Harmony Biosciences Preannounces Record Quarterly Revenue for Q2 2026, Reaffirms Full-Year 2026 Revenue Guidance, and Announces CFO Transition
Press releaseJun 11, 3:03 PM ETBusiness Wire
Paragon Advances Registration-Ready CNS Asset Addressing Important Unmet Need and Closes Sale to Teva Pharmaceutical
Press releaseJun 11, 8:05 AM ETBusiness Wire
Harmony Biosciences Announces Poster Presentations at 2026 SLEEP Annual Meeting
Press releaseMay 27, 8:05 AM ETBusiness Wire
Harmony Biosciences to Participate in Upcoming Investor Conferences
NewsMay 7, 7:38 AM ET
Harmony Biosciences Q1 Adj. EPS $0.55 Misses $0.69 Estimate, Sales $215.400M Miss $225.227M Estimate
Press releaseMay 7, 7:30 AM ETBusiness Wire
Harmony Biosciences Reports Q1 Financial Results and Confirms 2026 Net Revenue Guidance of Over $1 Billion; Reinforces 2026 Strategic Priorities
Press releaseApr 23, 8:05 AM ETBusiness Wire
Harmony Biosciences to Report First Quarter 2026 Financial Results on May 7, 2026
NewsApr 21, 5:05 PM ET
12 Health Care Stocks Moving In Tuesday's After-Market Session
Press releaseApr 16, 8:05 AM ETBusiness Wire
Harmony Biosciences to Present Open-Label Extension Data From Phase 3 ARGUS Trial at the 2026 American Academy of Neurology Annual Meeting
Press releaseApr 14, 8:05 AM ETBusiness Wire
Harmony Biosciences Appoints Glenn Reicin as Chief Financial Officer
Press releaseApr 2, 8:05 AM ETBusiness Wire
Harmony Biosciences Strengthens Executive Team With New Appointment and Announces Additions to Its Board
Press releaseMar 31, 8:05 AM ETBusiness Wire
Harmony Biosciences to Participate in 25th Annual Needham Virtual Healthcare Conference
Press releaseMar 4, 8:05 AM ETBusiness Wire
Harmony Biosciences to Participate in Upcoming Investor Conferences
NewsFeb 24, 7:32 AM ET
Harmony Biosciences Hldgs Earnings Review: Q4 Summary
NewsFeb 24, 7:31 AM ET
Harmony Biosciences Q4 Adj. EPS $0.57 Misses $0.90 Estimate, Sales $243.776M Beat $240.286M Estimate
Press releaseFeb 24, 7:30 AM ETBusiness Wire
Harmony Biosciences Reports Strong 2025 Financial Results and Reiterates 2026 Net Revenue Guidance of Over $1 Billion
NewsFeb 24, 6:11 AM ET
Earnings Scheduled For February 24, 2026
NewsFeb 20, 12:05 PM ET
12 Health Care Stocks Moving In Friday's Intraday Session
NewsFeb 17, 8:08 AM ET
The FDA Approves Harmony Biosciences' Supplemental Application For Wakix (Pitolisant) Tablets For Cataplexy In Pediatric Patients 6 Years Of Age And Older With Narcolepsy
Press releaseFeb 17, 8:05 AM ETBusiness Wire
Harmony Biosciences Receives U.S. Food and Drug Administration Approval for WAKIX® (pitolisant) for the Treatment of Cataplexy in Pediatric Narcolepsy
Press releaseFeb 10, 8:05 AM ETBusiness Wire
Harmony Biosciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
Press releaseJan 12, 8:05 AM ETBusiness Wire
Harmony Biosciences Guides to Over $1 Billion in WAKIX® Revenue in 2026; Advancing Robust Late-Stage Pipeline With Potential for Long-term Value Creation
Press releaseJan 7, 8:05 AM ETBusiness Wire
Harmony Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
Press releaseDec 8, 8:05 AM ETBusiness Wire
Harmony Biosciences Presents Clinically Meaningful Open-Label Extension Study Effectiveness Data for EPX-100 in Dravet Syndrome
Press releaseDec 2, 8:05 AM ETBusiness Wire
Harmony Biosciences to Present New Open-Label Extension Data from Phase 3 ARGUS Trial at the 2025 American Epilepsy Society Annual Meeting
Press releaseNov 24, 8:05 AM ETBusiness Wire
Harmony Biosciences Announces Positive Results From the Pivotal Bioequivalence Study for Pitolisant Gastro-Resistant Formulation
Press releaseNov 19, 8:05 AM ETBusiness Wire
Harmony Biosciences Announces Initiation of First-In-Human Study With Potential Best-In-Class Orexin 2 Receptor Agonist (BP1.15205) for Central Disorders of Hypersomnolence
Press releaseNov 18, 8:05 AM ETBusiness Wire
Harmony Biosciences to Participate in Upcoming Investor Conferences
Press releaseNov 4, 7:30 AM ETBusiness Wire
Harmony Biosciences Reports Strong Q3 2025 Financial Results; Recently Raised 2025 Revenue Guidance to $845-$865M
Press releaseOct 23, 8:05 AM ETBusiness Wire
Harmony Biosciences Preannounces Strong Q3 2025 WAKIX Performance; Raises 2025 Revenue Guidance
NewsOct 6, 6:23 AM ETAvi Kapoor
Top 3 Health Care Stocks That Are Preparing To Pump In Q4
NewsSep 25, 6:01 PM ET
Deep Dive Into Harmony Biosciences Hldgs Stock: Analyst Perspectives (6 Ratings)
NewsSep 24, 1:20 PM ETVandana Singh
Harmony Biosciences' Genetic Disorder Drug Disappoints In Phase 3 Study
NewsSep 24, 8:10 AM ET
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Press releaseSep 24, 8:00 AM ETBusiness Wire
Harmony Biosciences Provides Update From Its Phase 3 RECONNECT Study of ZYN002 in Fragile X Syndrome
Press releaseAug 26, 8:05 AM ETBusiness Wire
Harmony Biosciences to Present Rare Epilepsy Data at the 36th International Epilepsy Congress

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Harmony Biosciences Announces Planned CEO Transition to Support Next Phase of Growth

Harmony Biosciences Says New Data Supports Neurology Pipeline

Harmony Biosciences Q2 EPS $1.28 Beats $0.94 Estimate, Sales $261.300M Beat $248.406M Estimate

Harmony Biosciences Announces Record Q2 2026 Revenue and Shares Initial Clinical Data for Its Orexin-2 Agonist BP-205 Reinforcing Potential Best-in-Class Profile

Harmony Biosciences Preannounces Record Quarterly Revenue for Q2 2026, Reaffirms Full-Year 2026 Revenue Guidance, and Announces CFO Transition

Paragon Advances Registration-Ready CNS Asset Addressing Important Unmet Need and Closes Sale to Teva Pharmaceutical

Harmony Biosciences Announces Poster Presentations at 2026 SLEEP Annual Meeting

Harmony Biosciences to Participate in Upcoming Investor Conferences

Harmony Biosciences Q1 Adj. EPS $0.55 Misses $0.69 Estimate, Sales $215.400M Miss $225.227M Estimate

Harmony Biosciences Reports Q1 Financial Results and Confirms 2026 Net Revenue Guidance of Over $1 Billion; Reinforces 2026 Strategic Priorities

Harmony Biosciences to Report First Quarter 2026 Financial Results on May 7, 2026

12 Health Care Stocks Moving In Tuesday's After-Market Session

Harmony Biosciences to Present Open-Label Extension Data From Phase 3 ARGUS Trial at the 2026 American Academy of Neurology Annual Meeting

Harmony Biosciences Appoints Glenn Reicin as Chief Financial Officer

Harmony Biosciences Strengthens Executive Team With New Appointment and Announces Additions to Its Board

Harmony Biosciences to Participate in 25th Annual Needham Virtual Healthcare Conference

Harmony Biosciences to Participate in Upcoming Investor Conferences

Harmony Biosciences Hldgs Earnings Review: Q4 Summary

Harmony Biosciences Q4 Adj. EPS $0.57 Misses $0.90 Estimate, Sales $243.776M Beat $240.286M Estimate

Harmony Biosciences Reports Strong 2025 Financial Results and Reiterates 2026 Net Revenue Guidance of Over $1 Billion

Earnings Scheduled For February 24, 2026

12 Health Care Stocks Moving In Friday's Intraday Session

The FDA Approves Harmony Biosciences' Supplemental Application For Wakix (Pitolisant) Tablets For Cataplexy In Pediatric Patients 6 Years Of Age And Older With Narcolepsy

Harmony Biosciences Receives U.S. Food and Drug Administration Approval for WAKIX® (pitolisant) for the Treatment of Cataplexy in Pediatric Narcolepsy

Harmony Biosciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

Harmony Biosciences Guides to Over $1 Billion in WAKIX® Revenue in 2026; Advancing Robust Late-Stage Pipeline With Potential for Long-term Value Creation

Harmony Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference

Harmony Biosciences Presents Clinically Meaningful Open-Label Extension Study Effectiveness Data for EPX-100 in Dravet Syndrome

Harmony Biosciences to Present New Open-Label Extension Data from Phase 3 ARGUS Trial at the 2025 American Epilepsy Society Annual Meeting

Harmony Biosciences Announces Positive Results From the Pivotal Bioequivalence Study for Pitolisant Gastro-Resistant Formulation

Harmony Biosciences Announces Initiation of First-In-Human Study With Potential Best-In-Class Orexin 2 Receptor Agonist (BP1.15205) for Central Disorders of Hypersomnolence

Harmony Biosciences to Participate in Upcoming Investor Conferences

Harmony Biosciences Reports Strong Q3 2025 Financial Results; Recently Raised 2025 Revenue Guidance to $845-$865M

Harmony Biosciences Preannounces Strong Q3 2025 WAKIX Performance; Raises 2025 Revenue Guidance

Top 3 Health Care Stocks That Are Preparing To Pump In Q4

Deep Dive Into Harmony Biosciences Hldgs Stock: Analyst Perspectives (6 Ratings)

Harmony Biosciences' Genetic Disorder Drug Disappoints In Phase 3 Study

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Harmony Biosciences Provides Update From Its Phase 3 RECONNECT Study of ZYN002 in Fragile X Syndrome

Harmony Biosciences to Present Rare Epilepsy Data at the 36th International Epilepsy Congress